The deadline for submissions to the post-market review of COPD medicines has been extended. The review was given the green light by the PBAc in August following concerns about the multiple use of a number of new combinations available on the PBS, including long-acting muscarinic antagonist (LAMA)/LABA and LABA/inhaled corticosteroid (ICS) combinations. You now have until ...
Already a member?
Enter your email to keep reading.